Ruben Raychaudhuri

9 posts

Ruben Raychaudhuri

Ruben Raychaudhuri

@RubenRaychaud

Assistant professor @fredhutch @uwmedicine former @pennIMresidents . interested in GU medical oncology, clinical trials

Seattle, WA Beigetreten Haziran 2023
149 Folgt117 Follower
Ruben Raychaudhuri retweetet
Uromigos
Uromigos@Uromigos·
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Omar Mian discusses: Metastasis-directed Therapy in Prostate Cancer.
English
0
16
28
12.5K
Ruben Raychaudhuri retweetet
Ruben Raychaudhuri retweetet
European Urology
European Urology@EUplatinum·
Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial by @RubenRaychaud et al. Full article: europeanurology.com/article/S0302-…
European Urology tweet media
English
1
4
11
2K
Ruben Raychaudhuri retweetet
Dra. María Natalia Gandur Quiroga
💫🌟#Genomic Correlates of Prostate-Specific Membrane Antigen #PSMA Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study🌟💫 @OncoAlert @PGrivasMDPhD @JessicaHawleyMD @RubenRaychaud @LauraGrahamMD @ColinCPritchard @PCFnews @PCF_Science ascopubs.org/doi/10.1200/PO… 🔷️Purpose of the Study 🔹️ To evaluate the association between the mutational profile of metastatic castration-resistant prostate cancer (mCRPC) and the clinical efficacy of treatment with 177Lu-PSMA-617 (LuPSMA). 🔷️Methodology 🔹️ Retrospective multicenter analysis of 126 mCRPC patients who received LuPSMA and had next-generation sequencing (NGS) results. 🔹️ Comparison of treatment response, prostate-specific antigen progression-free survival (PSA PFS), and overall survival (OS) among genetically defined subgroups. 🚨Key Findings 🔹️ Presence of tumor suppressor gene (TSG) mutations was associated with shorter PSA PFS and OS. 🔹️Patients with DNA damage repair (DDR) gene mutations showed improved OS in multivariable analysis. 🔹️ PSMA expression did not show significant differences between DDR-deficient and DDR-proficient cohorts. 🔹️ Patients with ATM mutations demonstrated higher treatment response rates, longer PSA PFS, and better OS. 🔹️ #BRCA2 mutations were not associated with improved clinical outcomes. 🔹️ #CDK12 mutations were associated with poorer responses and shorter PSA PFS. 🔷️Conclusions 🔹️ Variability in clinical outcomes with #LuPSMA can be influenced by the tumor's mutational profile. 🔹️ Prospective studies are warranted to better define the clinical activity of LuPSMA in predetermined genomic subgroups. 🔷️ Limitations 🔹️ Retrospective nature of the study and small sample size of genomic subgroups. 🔹️ Limitations in measuring PSMA expression across multiple sites. #GenomicMedicine #ProstateCancer #PrecisionOncology #LuPSMA #CancerResearch #mCRPC
Dra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet media
Ciudad Autónoma de Buenos Aires, Argentina 🇦🇷 English
0
15
28
3.1K